Roundtable Discussion: Are We Ready for Continuous Trial Oversight? From Retrospective Evidence to Real-Time Decisions
- How real-time clinical trial monitoring could transform regulatory decision-making, reducing ‘dead time’ and accelerating approvals while maintaining scientific rigor
- What infrastructure, data pipelines, and governance models are required to enable continuous data flow between sponsors, sites, and regulators without compromising privacy or control
- Where real-time oversight creates new risks, including misinterpretation of interim signals, bias, or overreaction to early data trends
- How organizations must rethink evidence generation, moving from static submissions to dynamic, continuously evolving evidence strategies across the clinical and post‑marketing lifecycle